IHC ER-PR & HER2neu Test in UAE | 600 AED | DHA Accredited Pathology

Executive Summary & Core Metrics

Clinical Actionability: This quantitative immunohistochemistry (IHC) panel provides definitive ER, PR, and HER2/neu receptor status from FFPE breast tumour tissue, achieving 99.9% diagnostic sensitivity. Results directly enable targeted endocrine therapy and anti-HER2 monoclonal antibody stratification.
Accuracy Guarantee: 99.9% Diagnostic Sensitivity via ISO 9001:2015 Accredited Processing (Cert: INT/EGQ/2509DA/3139).
Premium Logistics: Secure Medical Courier Solid Tissue Specimen Retrieval. Temperature-controlled cold-chain transport from any Dubai/Sharjah location.
Clinical Guidance: Post-test telephonic guidance provided by DHA-licensed specialists to support clinical decision-making.
Insurance: Direct Billing Verification via WhatsApp +971 54 548 8731.

Test Overview & Methodology

The IHC ER-PR, HER2neu panel is the cornerstone immunohistochemistry test for breast cancer subtyping, quantifying estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2/neu) expression in formalin-fixed paraffin-embedded (FFPE) tissue. This guideline-driven assay directly informs targeted endocrine and anti-HER2 therapies, enabling personalised oncology care.

Feature	Our IHC ER-PR, HER2neu Test	Closest Alternative
Precision / Methodology	ISO-accredited IHC with automated staining & quantitative image analysis	Manual scoring or non-accredited local IHC
Turnaround Time	3 working days	5–7 days
Regulatory Compliance	DHA/MOHAP standardised, ISO 9001:2015 (Cert: INT/EGQ/2509DA/3139)	Variable; often lacks UAE-specific accreditation
Clinical Support	Post-test tele-guidance by board-certified oncologist/pathologist	Limited to printed report

Physician Insight & Safety Protocols

“As a DHA-licensed Specialist Diagnostic Radiology, I emphasize that while IHC ER-PR, HER2neu results are pivotal for treatment stratification, they must be interpreted in conjunction with complete clinical history and histopathological findings. Pre-analytical variables can influence staining; therefore, I recommend discussing all results with your oncologist before making therapy decisions. Ensure the FFPE specimen contains adequate viable tumour content (>10%) for reliable interpretation.”

— Mr. Prabhakar Reddy Kalathoor, Specialist Diagnostic Radiology, DHA License No. 61713011

Advisory & Medication Safety

⚠️ Important Clinical Notice: Do not discontinue any prescribed medication (including hormonal therapy, chemotherapy, or blood thinners) without explicit consultation with your treating physician. Abrupt changes can cause severe health risks.

Exclusion Criteria & Emergency Red Flags

Known allergy to local anaesthetics or biopsy materials – inform the pathologist or surgeon before tissue collection.
Active infection at the intended biopsy site; postpone the procedure until cleared by a physician.
For FFPE block submission: Insufficient tumour content (<10% viable tumour cells) may preclude accurate IHC interpretation.
Pregnant or breastfeeding patients: discuss the necessity of the test and any biopsy risk with your obstetrician; a physician’s prescription is required for the IHC assay itself.
Seek immediate medical attention if you develop fever >38°C, severe bleeding, expanding hematoma, or purulent discharge at the biopsy site.

* Pre-test information: IHC ER-PR, HER2neu can be performed with a valid doctor’s prescription. This prescription requirement does not apply to emergency surgical procedures.

Patient FAQ & Clinical Guidance

1. What is the role of IHC ER-PR, HER2neu testing in breast cancer management?

This IHC panel precisely quantifies hormone receptors and growth factor overexpression in breast tumour tissue. The results determine whether endocrine therapy or anti-HER2 monoclonal antibodies will be effective. This biomarker analysis is mandatory for all newly diagnosed invasive breast cancers under DHA oncology protocols, ensuring every UAE patient receives a personalised, evidence-based treatment plan.

2. How is the tissue sample collected for this test?

The test requires an existing FFPE tissue block or biopsy slide from a previous surgical resection or core needle biopsy. Our logistics team arranges a Secure Medical Courier Solid Tissue Specimen Retrieval service. The specimen is transported under strict temperature-controlled cold-chain conditions to our ISO-accredited laboratory. A digital chain-of-custody receipt is provided at the point of collection.

3. What does an equivocal (2+) HER2 result mean?

An equivocal 2+ HER2 IHC result indicates intermediate cell membrane staining. This requires reflex testing via in-situ hybridisation (FISH/CISH) to definitively determine HER2 gene amplification status before anti-HER2 therapy can be initiated. Our report will clearly state the reflex recommendation, and our clinical counsellors can facilitate immediate FISH testing through your oncologist, ensuring zero treatment delay.

UAE Regulatory & Data Privacy Adherence

Trust & Compliance Framework

DNA Labs UAE strictly adheres to the UAE’s comprehensive legal framework for health data and personal privacy:

Data Protection: Fully compliant with Federal Decree-Law No. 45 of 2021 on Personal Data Protection (PDPL).
Health Information Governance: Aligned with Federal Law No. 2 of 2019 Concerning the Use of Information and Communication Technology in Health Fields.
Medical Liability: Clinical testing safety and patient consent governed by Federal Decree-Law No. 4 of 2016 on Medical Liability.
Accreditation: ISO 9001:2015 certified (Cert: INT/EGQ/2509DA/3139) and DHA licensed (Facility No: 1143).

Clinical & Logistical Metadata

Test Name	IHC ER-PR & HER2neu Panel
Price (AED)	600 AED
Turnaround Time	3 working days
Sample Type / Matrix	Archival Tissue Specimen (Formalin-Fixed Paraffin-Embedded Block / Biopsy Slides)
Methodology Used	Automated Immunohistochemistry (IHC) with Quantitative Image Analysis
ICD-10-CM Code	C50.919
LOINC Code	85319-2 (ER), 85318-4 (PR), 85321-8 (HER2)
DHA Facility License & Address	License No: 1143 \| Premises 105, Floor 1, Building 33, Dubai Healthcare City, Dubai, UAE